LTD "Multiprofile Clinic Consilium Medulla"

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Bladder cancer1 trial
• Childhood cancers1 trial
• Chronic spontaneous urticaria1 trial
• Gout1 trial
• Hidradenitis suppurativa1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Migraine1 trial
• Pancreatic cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 35 trials
• Phase 24 trials

Status

• Active, not recruiting3 trials
• Completed2 trials
• Terminated2 trials
• Not yet recruiting1 trial
• Recruiting1 trial

Lead sponsor

• G1 Therapeutics, Inc.2 trials
• Celldex Therapeutics1 trial
• EQRx, Inc.1 trial
• Immuneering Corporation1 trial
• Ipsen1 trial
• and 3 more

Running trials

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Immuneering Corporation· Source

  Contact: Tamta Makharadze, MD

• Recruiting

  A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

  NCT07384975· Phase 2· Navigator Medicines, Inc.· Source

  Contact: Associate Director, Clinical Operations

• Active, not recruiting

  A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

  NCT06625060· Phase 2· Ipsen· Source

• Active, not recruiting

  A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

  NCT06455202· Phase 3· Celldex Therapeutics· Source

• Active, not recruiting

  Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

  NCT05352672· Phase 3· Regeneron Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Hidradenitis suppurativa1 recruiting
• Pancreatic cancer1 recruiting

Closed trials

• Completed

  Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

  NCT05586958· Phase 3· LG Chem· Source

• Terminated

  A Study of Lerociclib in Participants With Advanced Breast Cancer

  NCT05085002· Phase 2· EQRx, Inc.· Source

• Terminated

  Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

  NCT04887831· Phase 2· G1 Therapeutics, Inc.· Source

• Completed

  Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

  NCT04799249· Phase 3· G1 Therapeutics, Inc.· Source